Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 8/20 | 0.47 |
| ▸ | MEN1 | O00255 | 6/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | AHR | P35869 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.42 |
| ▸ | NPC1 | O15118 | 4/20 | 0.42 |
| ▸ | RAB9A | P51151 | 4/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19283212 | 0.83 | MAPT (0.56) | ALDH1A1KDM4EMAPTMEN1KMT2A | |
| SCHEMBL13664206 | 0.83 | MAPT (0.56) | ALDH1A1KDM4EMAPTMEN1KMT2A | |
| SCHEMBL19283214 | 0.83 | MAPT (0.56) | ALDH1A1KDM4EMAPTMEN1KMT2A | |
| SCHEMBL13259398 | 0.82 | MAPT (0.53) | ALDH1A1KDM4EMAPTMEN1KMT2A | |
| SCHEMBL518402 | 0.82 | ALDH1A1 (0.53) | ALDH1A1KDM4EMAPTMEN1KMT2A | |
| SCHEMBL11072694 | 0.81 | CA1 (0.54) | ALDH1A1KDM4EMAPTMEN1KMT2A | |
| SCHEMBL11072695 | 0.81 | CA1 (0.54) | ALDH1A1KDM4EMAPTMEN1KMT2A | |
| SCHEMBL519184 | 0.81 | SMN1; SMN2 (0.55) | ALDH1A1KDM4EMAPTMEN1KMT2A | |
| SCHEMBL11860787 | 0.81 | MAPT (0.56) | ALDH1A1KDM4EMAPTMEN1KMT2A | |
| SCHEMBL8369509 | 0.81 | MAPT (0.42) | ALDH1A1KDM4EMAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170114044-A1 | PYRIDAZINONE COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS AND METHODS OF TREATING DISORDERS | TAKEDA PHARMACEUTICALS CO (JP) | 2017-04-27 | — | — | US | disclosed |
| US-20170114044-A1 | PYRIDAZINONE COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS AND METHODS OF TREATING DISORDERS | TAKEDA PHARMACEUTICALS CO (JP) | 2017-04-27 | — | — | US | disclosed |
| US-20170114044-A1 | PYRIDAZINONE COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS AND METHODS OF TREATING DISORDERS | TAKEDA PHARMACEUTICALS CO (JP) | 2017-04-27 | — | — | US | disclosed |
| US-9550756-B2 | Pyridazinone compounds as phosphodiesterase inhibitors and methods of treating disorders | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-01-24 | — | — | US | disclosed |
| US-9550756-B2 | Pyridazinone compounds as phosphodiesterase inhibitors and methods of treating disorders | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-01-24 | — | — | US | disclosed |
| US-9550756-B2 | Pyridazinone compounds as phosphodiesterase inhibitors and methods of treating disorders | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-01-24 | — | — | US | disclosed |
| EP-3006031-A1 | PYRIDAZINONE COMPOUNDS | Takeda Pharmaceutical Company Limited (JP) | 2016-04-13 | — | — | EP | disclosed |
| EP-3006031-A1 | PYRIDAZINONE COMPOUNDS | Takeda Pharmaceutical Company Limited (JP) | 2016-04-13 | — | — | EP | disclosed |
| EP-2393360-B1 | PYRIDAZINONE COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2015-11-04 | — | — | EP | disclosed |
| EP-2393360-B1 | PYRIDAZINONE COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2015-11-04 | — | — | EP | disclosed |
| US-20120028951-A1 | PYRIDAZINONE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-02-02 | — | — | US | disclosed |
| EP-2393360-A1 | PYRIDAZINONE COMPOUNDS | Takeda Pharmaceutical Company Limited (JP) | 2011-12-14 | — | — | EP | disclosed |
| WO-2010090737-A1 | PYRIDAZINONE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-12 | — | — | WO | disclosed |
| US-20100197651-A1 | Pyridazinone compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-05 | — | — | US | disclosed |
| US-20100197651-A1 | Pyridazinone compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-05 | — | — | US | disclosed |
| US-20100197651-A1 | Pyridazinone compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-05 | — | — | US | disclosed |
| EP-0869956-B1 | PHARMACEUTICAL COMPOSITIONS | KNOLL AG (DE) | 2001-08-08 | — | — | EP | disclosed |
| US-5877175-A | 3-(PYRIMIDIN-4-YL)-1-PHENYLPYRIDAZIN-4(1H)-ONES, TREATMENT OF SEIZURES AND/OR NEUROLOGICAL DISORDERS SUCH AS EPILEPSY AND/OR CONDITIONS IN WHICH THERE IS NEUROLOGICAL DAMAGE SUCH AS BRAIN TRAUMA, CEREBRAL ISCHAEMIA, HEMORRHAGE, HEAD INJURIES AND | KNOLL AKTIENGESELLSCHAFT (DE) | 1999-03-02 | — | — | US | disclosed |
| EP-0869956-A1 | PHARMACEUTICAL COMPOSITIONS | KNOLL AKTIENGESELLSCHAFT (DE) | 1998-10-14 | — | — | EP | disclosed |
| WO-1996030364-A1 | PHARMACEUTICAL COMPOSITIONS | KNOLL AKTIENGESELLSCHAFT (DE) | 1996-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170114044-A1 | PYRIDAZINONE COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS AND METHODS OF TREATING DISORDERS | PDE3A, PDE5A, PDE3B | ALDH1A1 343/4885KDM4E 1652/4885MAPT 4321/4885 |
| US-20120028951-A1 | PYRIDAZINONE COMPOUNDS | PDE3A, PDE5A, PDE3B | ALDH1A1 350/4885KDM4E 1514/4885MAPT 4105/4885 |
| US-20100197651-A1 | Pyridazinone compounds | PDE3A, PDE5A, PDE3B | ALDH1A1 334/4885KDM4E 1502/4885MAPT 4144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.